Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017
147 páginas : gráficas
- Autores:
-
Pérez Pedraza, Irma Patricia
Medina, Alba María
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2019
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/1923
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/1923
- Palabra clave:
- Etanercept - Efectos secundarios
Artritis Reumatoide - Tratamiento
Farmacovigilancia
Medicamentos - Efectos secundarios
Etanercept
Farmacovigilancia
Productos Biológicos
- Rights
- openAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
| id |
RepoUDCA2_c87220ec319978bb792ee94b460b3418 |
|---|---|
| oai_identifier_str |
oai:repository.udca.edu.co:11158/1923 |
| network_acronym_str |
RepoUDCA2 |
| network_name_str |
Repositorio Institucional UDCA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| title |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| spellingShingle |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 Etanercept - Efectos secundarios Artritis Reumatoide - Tratamiento Farmacovigilancia Medicamentos - Efectos secundarios Etanercept Farmacovigilancia Productos Biológicos |
| title_short |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| title_full |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| title_fullStr |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| title_full_unstemmed |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| title_sort |
Estudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017 |
| dc.creator.fl_str_mv |
Pérez Pedraza, Irma Patricia Medina, Alba María |
| dc.contributor.advisor.spa.fl_str_mv |
Sabogal Carmona, Juan Sebastián, dir. |
| dc.contributor.author.spa.fl_str_mv |
Pérez Pedraza, Irma Patricia Medina, Alba María |
| dc.subject.mesh.spa.fl_str_mv |
Etanercept - Efectos secundarios Artritis Reumatoide - Tratamiento Farmacovigilancia |
| topic |
Etanercept - Efectos secundarios Artritis Reumatoide - Tratamiento Farmacovigilancia Medicamentos - Efectos secundarios Etanercept Farmacovigilancia Productos Biológicos |
| dc.subject.lemb.spa.fl_str_mv |
Medicamentos - Efectos secundarios |
| dc.subject.proposal.spa.fl_str_mv |
Etanercept Farmacovigilancia Productos Biológicos |
| description |
147 páginas : gráficas |
| publishDate |
2019 |
| dc.date.accessioned.spa.fl_str_mv |
2019-08-06T21:48:13Z |
| dc.date.available.spa.fl_str_mv |
2019-08-06T21:48:13Z |
| dc.date.issued.spa.fl_str_mv |
2019 |
| dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
| format |
http://purl.org/coar/resource_type/c_7a1f |
| status_str |
publishedVersion |
| dc.identifier.uri.spa.fl_str_mv |
https://repository.udca.edu.co/handle/11158/1923 |
| dc.identifier.local.spa.fl_str_mv |
QF032 P27e 2019 (205605) |
| url |
https://repository.udca.edu.co/handle/11158/1923 |
| identifier_str_mv |
QF032 P27e 2019 (205605) |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
Rego-Perez. M. I; Fernandez-Moreno; Blanco. F., 2008. Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis., Curr. Genomics. 9 (6): 381– 393. Asanuma. Y; Xie. H. G; Stein. C. M., 2005. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 52 (5): 1349–1359. Osorio. Y.P; Amariles. P; Aristizabal, B.H; Pinto. L.F; Calleja. M.A., 2018. Farmacogenómica de etanercept, infliximab, adalimumab y metotrexato en artritis reumatoide, Revisión estructurada. Rev Colomb Reumatol; 25(1):22– 37. Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA-, 2009. Comunicado INVIMA Advertencia del INVIMA sobre posibles efectos colaterales de medicamentos bloqueadores del Factor de Necrosis Tumoral. Disponible desde internet en: http://www.invima.gov.co/Invima/general/docs_popup/informacion_reumatologos.pdf. H. T. Scott DL, Wolfe F, “Rheumatoid arthritis.,” Lancet, vol. 376, pp. 1094– 1108, 2010. Muñetón. G.A; Quintana. G., 2015. La epidemiología de la artritis reumatoide. Rev Colomb Reumatol; 22(3):145–147. Sabogal Carmona, J. S., Díaz Rodríguez, E. A., & Espinosa Espinosa, I. I. (2013). Fundamentos de farmacovigilancia. Bogotá: ISBN Valor. L; De La Torre. I., 2013. Comprender el concepto de inmunogenicidad. Reumatol Clin. 9 (1):1-4. Saag. K. G. et al., 2008. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res. 59 (6): 762–784. Rego-Perez. M. I; Fernandez-Moreno; Blanco. F., 2008. Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis., Curr. Genomics. 9 (6): 381–393. Asanuma. Y; Xie. H. G; Stein. C. M., 2005. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 52 (5): 1349–1359. Cuartas. J.E.A et al. 2013. Descripción del estado de salud y calidad de vida en pacientes tratados con etanercept dentro de un programa de atención para artritis reumatoide en un centro especializado en Colombia. Rev Colomb Reumatol; 22(3):122–127. Malerich. P; Elston. DM., 2006. TNF-alpha Inhibitors. Basel, Germany, Milestone in Drug Therapy, Birkhauser Verlag, 1-2. Osorio. Y.P; Amariles. P; Aristizabal, B.H; Pinto. L.F; Calleja. M.A., 2018. Farmacogenómica de etanercept, infliximab, adalimumab y metotrexato en artritis reumatoide, Revisión estructurada. Rev Colomb Reumatol; 25(1):22–37. . Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA-, 2009. Comunicado INVIMA Advertencia del INVIMA sobre posibles efectos colaterales de medicamentos bloqueadores del Factor de Necrosis Tumoral. Disponible desde internet en: http://www.invima.gov.co/Invima/general/docs_popup/informacion_reumatologos.pdf. Wu. H; Liao. J; Li. Q; Yang. M; Zhao. M; Lu. Q., 2018. Epigenetics as biomarkers in autoimmune diseases. Clin Immunol., 196(Nov):34-39. Noel. R.R.; Ian R. M, 2014. The Autoimmune Diseases, 5ª ed. San Diego USA; Academic Press, 19-21. Firestein. GS.; 2003. Evolving concepts of rheumatoid arthritis. Rheumatoid arthritis the most common inflammatory arthritis and is a major cause of disability. Nature, 423. 356 – 361. Machold KP, Stamm TA, Eberl GJM, et al. 2002. Very recent onset arthritis: clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol. 29. 2278–2287. McInnes. I.B; Schett. G.; 2011. The Pathogenesis of rheumatoid arthritis. N. Eng. J. Med.; 365 (23):2205-19. Ruiz-Esquide. V; Sanmartí. R.; 2012. Tabaco y otros factores ambientales en la artritis reumatoide. Reumatol Clín; 8(S6):S303-S382. Malerich. P; Elston. DM., 2006. TNF-alpha Inhibitors. Basel, Germany, Milestone in Drug Therapy, Birkhauser Verlag. Germany. 4-6. Ball. R.J; Avenell. A; Aucott. L; Hanlon. P; Vickers. M.A; 2015. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Res Ther. (17): 274. Liao. K.P; Alfredsson. L; Karlson. E.W. 2009. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 21 (3):279-83. Schur. P.H; Firenstein. G.S. 2014. Pathogenesis of rheumatoid arthritis. Disponible desde internet en: http://www.uptodate.com. Takagi. H; Ishiguro. N; Iwata. H; Kanamono. T. 2000. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol. 27 (7):1638-42. Loza. E; Calvo. J; del Canto. F; Alarcón. G.S. 2006. Artritis Reumatoide en Enfermedades Autoinmunes. Barcelona. Masson., 369-99. Feldmann. M; Maini. S.R. 2008. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 223:7–19. . Holmdahl. R; Malmström. V; Burkhardt. H. 2014. Autoimmune priming, tissue attack and chronic inflammation — The three stages of rheumatoid arthritis. Eur J Immunol. Weinheim, Germany. Wiley-VCH Verlag GmbH & Co. 44 (66): 1593- 1599. Emery. P; 2015. Atlas of Rheumatoid Arthritis. London UK, Springer Healthcare Communications. 37. Ravelli. A. 2016. Handbook of Juvenile Idiopathic Arthritis. Genoa, Italy, Adis. 1-2. Warren. R; Menter. A.; 2016. Handbook of Psoriasis and Psoriatic Arthritis. Switzerland, Adis. 7-25. Sieper. J; Braun. J.; 2011. Ankylosing Spondylitis In Clinical Practice. London UK. Springer-Verlag. 5-11. Prots. I. et al., 2006. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum. 54 (5): 1491–1500. Kate. P. D; Pisetsky M., 2007. Early rheumatoid arthritis. Curr Opin Rheumatol. (19) 278–283. Greenstein. B; Brook. D.A.; 2011. Biological Therapeutics. London UK. Pharmaceutical Press. 90-94. Bergstra. S.A; Allaart. C. F; Stijnen. T; Landewé. R. B. M., 2017. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug–Naïve Early Rheumatoid Arthritis Patients. Arthritis Care Res. 69 (10): 1473–1483. Sizova. L., 2008. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br. J. Clin. Pharmacol. 66 (2): 173–178. Resman-Targoff. B. H; Cicero. M. P., 2010. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am. J. Manag. Care. 16 (9) Suppl: S249-58. Kuriya. B; Arkema. E. V; Bykerk. V. P; Keystone. E. C., 2010. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: A meta-analysis of clinical and radiographic remission. Ann. Rheum. Dis. 69 (7): 1298–1304. R.F. Van Vollenhoven., 2016. Biologics for the Treatment of Rheumatoid Arthritis; Stockolm, Sweden, Adis, 30-37. Bernal-Camargo. D.R; Gaitán-Bohórquez. J.C; León-Robayo. E.I., 2018. Medicamentos biosimilares en Colombia: una revisión desde el consumo informado. Rev Cienc Salud. 16 (2): 311-339. R.F. Van Vollenhoven., 2016. Biologics for the Treatment of Rheumatoid Arthritis; Stockolm, Sweden, Adis, 39-42. Brennan. F.M; Chantry. D; Jackson. A; Maini. R; Feldmann. M., 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:244-247 . Michaud. T.L; Rho. Y.H; Shamliyan. T; Kuntz. K.M; Choi. H.K., 2014. The Comparative Safety of TNF Inhibitors in Rheumatoid Arthritis - A Meta-Analysis Update of 44 Randomized Controlled Trials. Am J Med. Jun 17. Malerich. P, Elston. DM., 2006. TNF-alpha Inhibitors. Milestone in Drug Therapy, Birkhauser Verlag, Germany. 9-18. Choy. E.H.S; Panayi. G.S.; 2001. Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis N. Eng. J. Med. 22 (344):907-16. |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) |
| rights_invalid_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales https://creativecommons.org/licenses/by-nc-sa/4.0/ Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.coverage.spatial.spa.fl_str_mv |
Bogotá, Colombia |
| dc.coverage.temporal.spa.fl_str_mv |
2008-2017 |
| dc.publisher.spa.fl_str_mv |
Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019 |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
| dc.publisher.program.spa.fl_str_mv |
Química Farmacéutica |
| institution |
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A |
| bitstream.url.fl_str_mv |
https://repository.udca.edu.co/bitstreams/4eb1fbd1-72bc-41c3-bcf5-062cf5336c1f/download https://repository.udca.edu.co/bitstreams/8dedea30-0a45-43cf-801f-418388708225/download https://repository.udca.edu.co/bitstreams/60121352-2de3-4530-a1b6-99f30c161cff/download https://repository.udca.edu.co/bitstreams/48a12210-4eb8-484f-85b4-a30601528a23/download |
| bitstream.checksum.fl_str_mv |
b66cdb2a0436520a5524e402d8c5d42e f661acf14bedbf9f5d13897a0387e751 7ebfb5cf9af7efe43158f4e758d59d81 0c3291d2c6e1df79743d9e6208ce2abf |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA. |
| repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
| _version_ |
1814213314062843904 |
| spelling |
Sabogal Carmona, Juan Sebastián, dir.Pérez Pedraza, Irma PatriciaMedina, Alba MaríaBogotá, Colombia2008-20172019-08-06T21:48:13Z2019-08-06T21:48:13Z2019https://repository.udca.edu.co/handle/11158/1923QF032 P27e 2019 (205605)147 páginas : gráficasLa proteína de fusión dimérica Etanercept está indicada en el tratamiento de Artritis Reumatoide activa, Artritis Idiopática Juvenil, psoriasis, artritis psoriásica y espondilitis anquilosante. Aunque esta terapia biológica ha demostrado ser muy eficaz en pacientes con Artritis Reumatoide, se han encontrado reportes sobre problemas de variabilidad en la respuesta biológica y eventos adversos, lo que conlleva a inefectividad terapéutica y reacciones adversas los pacientes. En el periodo comprendido del estudio entre los años 2008 - 2017 el programa distrital de farmacovigilancia de la secretaria de salud de Bogotá recibió un total de 198 reportes donde se considera como medicamento sospechoso el Etanercept. De los 198 reportes, 15 reportes fueron identificados como problemas relacionados al medicamento y 183 reportes como reacciones adversas al medicamento. A partir de los 183 reportes de reacciones adversas se identificaron un total de 229 descriptores WHOART, los cuales permitieron evidenciar una clara preponderancia de reportes de reacciones adversas tipo falta de efecto terapéutico con un 10,48%. Así mismo, se evidenció un número importante de reportes de reacciones adversas tipo cefalea al igual que reacciones adversas que se desarrollan en el sitio de la inyección, las que involucran al sistema inmunológico e infecciones de las vías urinarias y del tracto respiratorio.Introduction: The dimeric fusion protein Etanercept is indicated in the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis. Although this biological therapy has proven to be very effective in patients with rheumatoid arthritis, reports have been found on problems of variability in biological response and adverse events, which leads to therapeutic ineffectiveness and adverse reactions in patients. In the period covered by the study between the years 2008 - 2017, the district pharmacovigilance program of the health secretary of Bogotá received a total of 198 reports where Etanercept is considered a suspicious drug. Of the 198 reports, 15 reports were identified as problems related to the medication and 183 reports as adverse reactions to the medication. From the 183 reports of adverse reactions, a total of 229 WHOART descriptors were identified, which allowed to show a clear preponderance of reports of adverse reactions of a lack of therapeutic effect with 10.48%. Likewise, an important number of reports of headache type adverse reactions were evidenced as well as adverse reactions developed at the injection site, those involve the immune system and infections of the urinary tract and respiratory tract.Incluye bibliografíaPregradoQuímico(a) Farmacéuticoapplication/pdfspaBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica FarmacéuticaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientaleshttps://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)http://purl.org/coar/access_right/c_abf2Etanercept - Efectos secundariosArtritis Reumatoide - TratamientoFarmacovigilanciaMedicamentos - Efectos secundariosEtanerceptFarmacovigilanciaProductos BiológicosEstudio descriptivo de reacciones adversas al medicamento y problemas relacionados al medicamento Etanercept reportados en Bogotá D. C. 2008-2017Trabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Rego-Perez. M. I; Fernandez-Moreno; Blanco. F., 2008. Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis., Curr. Genomics. 9 (6): 381– 393.Asanuma. Y; Xie. H. G; Stein. C. M., 2005. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 52 (5): 1349–1359.Osorio. Y.P; Amariles. P; Aristizabal, B.H; Pinto. L.F; Calleja. M.A., 2018. Farmacogenómica de etanercept, infliximab, adalimumab y metotrexato en artritis reumatoide, Revisión estructurada. Rev Colomb Reumatol; 25(1):22– 37.Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA-, 2009. Comunicado INVIMA Advertencia del INVIMA sobre posibles efectos colaterales de medicamentos bloqueadores del Factor de Necrosis Tumoral. Disponible desde internet en: http://www.invima.gov.co/Invima/general/docs_popup/informacion_reumatologos.pdf.H. T. Scott DL, Wolfe F, “Rheumatoid arthritis.,” Lancet, vol. 376, pp. 1094– 1108, 2010.Muñetón. G.A; Quintana. G., 2015. La epidemiología de la artritis reumatoide. Rev Colomb Reumatol; 22(3):145–147.Sabogal Carmona, J. S., Díaz Rodríguez, E. A., & Espinosa Espinosa, I. I. (2013). Fundamentos de farmacovigilancia. Bogotá: ISBNValor. L; De La Torre. I., 2013. Comprender el concepto de inmunogenicidad. Reumatol Clin. 9 (1):1-4.Saag. K. G. et al., 2008. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res. 59 (6): 762–784.Rego-Perez. M. I; Fernandez-Moreno; Blanco. F., 2008. Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis., Curr. Genomics. 9 (6): 381–393.Asanuma. Y; Xie. H. G; Stein. C. M., 2005. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 52 (5): 1349–1359.Cuartas. J.E.A et al. 2013. Descripción del estado de salud y calidad de vida en pacientes tratados con etanercept dentro de un programa de atención para artritis reumatoide en un centro especializado en Colombia. Rev Colomb Reumatol; 22(3):122–127.Malerich. P; Elston. DM., 2006. TNF-alpha Inhibitors. Basel, Germany, Milestone in Drug Therapy, Birkhauser Verlag, 1-2.Osorio. Y.P; Amariles. P; Aristizabal, B.H; Pinto. L.F; Calleja. M.A., 2018. Farmacogenómica de etanercept, infliximab, adalimumab y metotrexato en artritis reumatoide, Revisión estructurada. Rev Colomb Reumatol; 25(1):22–37.. Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA-, 2009. Comunicado INVIMA Advertencia del INVIMA sobre posibles efectos colaterales de medicamentos bloqueadores del Factor de Necrosis Tumoral. Disponible desde internet en: http://www.invima.gov.co/Invima/general/docs_popup/informacion_reumatologos.pdf.Wu. H; Liao. J; Li. Q; Yang. M; Zhao. M; Lu. Q., 2018. Epigenetics as biomarkers in autoimmune diseases. Clin Immunol., 196(Nov):34-39.Noel. R.R.; Ian R. M, 2014. The Autoimmune Diseases, 5ª ed. San Diego USA; Academic Press, 19-21.Firestein. GS.; 2003. Evolving concepts of rheumatoid arthritis. Rheumatoid arthritis the most common inflammatory arthritis and is a major cause of disability. Nature, 423. 356 – 361.Machold KP, Stamm TA, Eberl GJM, et al. 2002. Very recent onset arthritis: clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol. 29. 2278–2287.McInnes. I.B; Schett. G.; 2011. The Pathogenesis of rheumatoid arthritis. N. Eng. J. Med.; 365 (23):2205-19.Ruiz-Esquide. V; Sanmartí. R.; 2012. Tabaco y otros factores ambientales en la artritis reumatoide. Reumatol Clín; 8(S6):S303-S382.Malerich. P; Elston. DM., 2006. TNF-alpha Inhibitors. Basel, Germany, Milestone in Drug Therapy, Birkhauser Verlag. Germany. 4-6.Ball. R.J; Avenell. A; Aucott. L; Hanlon. P; Vickers. M.A; 2015. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Res Ther. (17): 274.Liao. K.P; Alfredsson. L; Karlson. E.W. 2009. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 21 (3):279-83.Schur. P.H; Firenstein. G.S. 2014. Pathogenesis of rheumatoid arthritis. Disponible desde internet en: http://www.uptodate.com.Takagi. H; Ishiguro. N; Iwata. H; Kanamono. T. 2000. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol. 27 (7):1638-42.Loza. E; Calvo. J; del Canto. F; Alarcón. G.S. 2006. Artritis Reumatoide en Enfermedades Autoinmunes. Barcelona. Masson., 369-99.Feldmann. M; Maini. S.R. 2008. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 223:7–19.. Holmdahl. R; Malmström. V; Burkhardt. H. 2014. Autoimmune priming, tissue attack and chronic inflammation — The three stages of rheumatoid arthritis. Eur J Immunol. Weinheim, Germany. Wiley-VCH Verlag GmbH & Co. 44 (66): 1593- 1599.Emery. P; 2015. Atlas of Rheumatoid Arthritis. London UK, Springer Healthcare Communications. 37.Ravelli. A. 2016. Handbook of Juvenile Idiopathic Arthritis. Genoa, Italy, Adis. 1-2.Warren. R; Menter. A.; 2016. Handbook of Psoriasis and Psoriatic Arthritis. Switzerland, Adis. 7-25.Sieper. J; Braun. J.; 2011. Ankylosing Spondylitis In Clinical Practice. London UK. Springer-Verlag. 5-11.Prots. I. et al., 2006. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum. 54 (5): 1491–1500.Kate. P. D; Pisetsky M., 2007. Early rheumatoid arthritis. Curr Opin Rheumatol. (19) 278–283.Greenstein. B; Brook. D.A.; 2011. Biological Therapeutics. London UK. Pharmaceutical Press. 90-94.Bergstra. S.A; Allaart. C. F; Stijnen. T; Landewé. R. B. M., 2017. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug–Naïve Early Rheumatoid Arthritis Patients. Arthritis Care Res. 69 (10): 1473–1483.Sizova. L., 2008. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br. J. Clin. Pharmacol. 66 (2): 173–178.Resman-Targoff. B. H; Cicero. M. P., 2010. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am. J. Manag. Care. 16 (9) Suppl: S249-58.Kuriya. B; Arkema. E. V; Bykerk. V. P; Keystone. E. C., 2010. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: A meta-analysis of clinical and radiographic remission. Ann. Rheum. Dis. 69 (7): 1298–1304.R.F. Van Vollenhoven., 2016. Biologics for the Treatment of Rheumatoid Arthritis; Stockolm, Sweden, Adis, 30-37.Bernal-Camargo. D.R; Gaitán-Bohórquez. J.C; León-Robayo. E.I., 2018. Medicamentos biosimilares en Colombia: una revisión desde el consumo informado. Rev Cienc Salud. 16 (2): 311-339.R.F. Van Vollenhoven., 2016. Biologics for the Treatment of Rheumatoid Arthritis; Stockolm, Sweden, Adis, 39-42.Brennan. F.M; Chantry. D; Jackson. A; Maini. R; Feldmann. M., 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:244-247. Michaud. T.L; Rho. Y.H; Shamliyan. T; Kuntz. K.M; Choi. H.K., 2014. The Comparative Safety of TNF Inhibitors in Rheumatoid Arthritis - A Meta-Analysis Update of 44 Randomized Controlled Trials. Am J Med. Jun 17.Malerich. P, Elston. DM., 2006. TNF-alpha Inhibitors. Milestone in Drug Therapy, Birkhauser Verlag, Germany. 9-18.Choy. E.H.S; Panayi. G.S.; 2001. Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis N. Eng. J. Med. 22 (344):907-16.PublicationORIGINALTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdfTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdfapplication/pdf2373600https://repository.udca.edu.co/bitstreams/4eb1fbd1-72bc-41c3-bcf5-062cf5336c1f/downloadb66cdb2a0436520a5524e402d8c5d42eMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-814775https://repository.udca.edu.co/bitstreams/8dedea30-0a45-43cf-801f-418388708225/downloadf661acf14bedbf9f5d13897a0387e751MD52TEXTTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdf.txtTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdf.txtExtracted texttext/plain237554https://repository.udca.edu.co/bitstreams/60121352-2de3-4530-a1b6-99f30c161cff/download7ebfb5cf9af7efe43158f4e758d59d81MD53THUMBNAILTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdf.jpgTRABAJO DE GRADO ETANERCEPT FINAL 20190727.pdf.jpgGenerated Thumbnailimage/jpeg3997https://repository.udca.edu.co/bitstreams/48a12210-4eb8-484f-85b4-a30601528a23/download0c3291d2c6e1df79743d9e6208ce2abfMD5411158/1923oai:repository.udca.edu.co:11158/19232024-05-09 14:32:27.819https://creativecommons.org/licenses/by-nc-sa/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesopen.accesshttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.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 |